B-Cell Malignant Neoplasm — Trials

B-Cell Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,083
Recruiting: 1,078
Ph III recruiting: 121
Growth YoY: +5.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,167)

clinicaltrialsPublishedShowing 51–100 of 905 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04268277	Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY	terminated	Phase 2	22	University of UlmOTHER	1	Feb 27, 2026	clinicaltrials
NCT03990961	Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)	terminated	Phase 2	5	University of ChicagoOTHER	1	Feb 20, 2026	clinicaltrials
NCT03031730